A new extra-vertebral treatment model for incomplete spinal cord injuries.
Advances made in recent times in spinal cord injury repair research will soon take us toward a cure in paraplegics. But what are the prospects for quadriplegics? Certain fundamental issues make treatment approaches to quadriplegia different and difficult. Injury at cervical region poses additional problems for any surgical intervention with life-threatening risks of i) endangering respiratory function, ii) cavitation, cysts, and syringomyelia formation extending cephalad to the injury, and iii) mid-lower cervical injuries, lower motor neuron death, and the resultant degeneration of brachial plexus axons would still leave the upper limbs denervated and paralyzed even as treatment procedures might successfully salvage the lower limbs. With these apparently insurmountable impediments in quadriplegic cord repair, it would be wise to turn to alternative treatment strategies. Conventional treatment models since the days of Ralph Gerard (1940) have all used intra-vertebral procedures. We present here a plausible extra-vertebral repair model suitable for incomplete cord injuries at cervical, thoracic, and lumbar levels. The procedure consists of identifying the extent of viable grey-white matter in the injured area and to utilize it efficiently as a "neural tissue bridge." Next, labile state is induced by using botulinum toxin/colchicine (Krishnan, 1983, 1991; Krishnan et al., 2001 a,b) and Ca+ channel blockers in the motorsensory nerve terminals of polisegmentally innervated skeletal muscles that "bridge" the injured cord segments. This would retrogradely induce a redundant state of intra-spinal growth of nerve terminals and new synaptic connections within those viable neural tissues, as well as promote effective relinking of the injured cord ends and enhance motor-sensory recovery.
Krishnan
R V
RV
Department of Anatomy, Dr. A. L. Mudaliar Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600 113, India. krish_venk@yahoo.com
D018726:Anti-Dyskinesia Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000494:pharmacology* / Q000627:therapeutic use*; D002118:Calcium / Q000494:pharmacology* / Q000627:therapeutic use*; D003078:Colchicine / Q000494:pharmacology* / Q000627:therapeutic use*; D004338:Drug Combinations; D006074:Gout Suppressants / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation; D011782:Quadriplegia / Q000209:etiology; D012120:Respiration Disorders / Q000209:etiology; D013119:Spinal Cord Injuries / Q000150:complications / Q000188:drug therapy*; D013131:Spine / Q000187:drug effects* / Q000294:innervation; D013569:Synapses / Q000187:drug effects
D018726:Anti-Dyskinesia Agents; D004338:Drug Combinations; D006074:Gout Suppressants; D001905:Botulinum Toxins; D003078:Colchicine; D002118:Calcium